These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29924456)

  • 1. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
    Conceição I; Miranda B; Castro J; de Carvalho M
    Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
    Socie P; Benmalek A; Cauquil C; Piekarski E; Kounis I; Eliahou L; Rousseau A; Rouzet F; Echaniz-Laguna A; Samuel D; Adams D; Slama MS; Algalarrondo V
    Amyloid; 2023 Sep; 30(3):303-312. PubMed ID: 36795029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.
    Monteiro C; Martins da Silva A; Ferreira N; Mesgarzadeh J; Novais M; Coelho T; Kelly JW
    Amyloid; 2018 Jun; 25(2):120-128. PubMed ID: 29993288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Labeyrie C; Merkel M; Sethi S; Popadic L; Yang H; Sweetser MT; Lin H; Adams D
    Eur J Neurol; 2024 Sep; 31(9):e16384. PubMed ID: 38988097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
    Sanso MAR; Rodriguez AR; Vicente LM; Sevilla T; Garro CB; Martín JF; Vicente AA; de la Prida MM; Dávila LG; Vázquez LG; Valle FM; Pons CC; Bau AF; Barroso EC; López IL; González-Moreno J
    Med Clin (Barc); 2024 May; 162(9):e27-e32. PubMed ID: 38556397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
    J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
    Gundapaneni BK; Sultan MB; Keohane DJ; Schwartz JH
    Eur J Neurol; 2018 Mar; 25(3):464-468. PubMed ID: 29115008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation.
    Okumura K; Yamashita T; Masuda T; Misumi Y; Ueda A; Ueda M; Obayashi K; Jono H; Yamashita S; Inomata Y; Ando Y
    Amyloid; 2016; 23(1):39-45. PubMed ID: 26763274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
    Cruz MW
    Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
    Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
    Lozeron P; Théaudin M; Mincheva Z; Ducot B; Lacroix C; Adams D;
    Eur J Neurol; 2013 Dec; 20(12):1539-45. PubMed ID: 23834402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
    Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
    Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.